858-692-3573 info@denovicontx.com

Biovia User Group Meeting 2022

On October 11, 2022, Denovicon Therapeutics Founder & CEO, Scott Bembenek, presented on ‘An AI–Molecular Modeling Platform for Streamlining Small-Molecule Drug Discovery’ at the Biovia User Group Meeting 2022.

Denovicon Founder to Present at SLAS 2022

On February 8, 2022, Denovicon Therapeutics Founder & CEO, Scott Bembenek talked (along with BIOVIA’s Guy Oshiro) at SLAS 2022 about how AI and the use of virtual–real cycles is revolutionizing the drug discovery process.

BIO Partnering at JPM 2022

Denovicon was pleased to participate in BIO Partnering at JPM 2022. If you’re interested in learning more about our AI/machine learning/molecular modeling platform and current molecular assets, feel free to reach out.

Biovia User Group Meeting 2021

On September 14, 2021, Denovicon Therapeutics Founder & CEO, Scott Bembenek, presented on Denovicon’s ‘AI–Molecular Modeling Platform for Enhanced Small-Molecule Drug Discovery’ at the Biovia User Group Meeting 2021.

AI in Drug Discovery 2021

On March 15, 2021, Denovicon Therapeutics Founder & CEO, Scott Bembenek, talked on ‘Combining Machine Learning and Molecular Modeling for Enhanced Active Learning in Small-Molecule Drug Design’ at the AI in Drug Discovery 2021.

Global Pharma R&D AI, Data Science and Informatics Summit 2020

On November 16, 2020, Denovicon Therapeutics Founder & CEO, Scott Bembenek, spoke at the Global Pharma R&D AI, Data Science and Informatics Summit (PRADI 2020) on ‘Combining Machine Learning and Molecular Modeling for Enhanced Active Learning in...